Dow Down0.18% Nasdaq Up0.39%

Discovery Laboratories Inc. (DSCO)

-NasdaqCM
1.80 Down 0.02(1.10%) Sep 2, 4:00PM EDT
ProfileGet Profile for:
Discovery Laboratories Inc.
2600 Kelly Road
Suite 100
Warrington, PA 18976
United States - Map
Phone: 215-488-9300
Website: http://www.discoverylabs.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:126

Business Summary 

Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing life-saving products for critical-care patients with respiratory disease and care in pulmonary medicine. Its drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant), as well as in liquid, lyophilized, and aerosolized dosage forms; and develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant. The company’s product includes SURFAXIN Intratracheal suspension for the prevention of respiratory distress syndrome (RDS) in premature infants. It is also developing AEROSURF, a drug-device combination product that is in Phase IIa clinical trials for the treatment of RDS in premature infants; and AFECTAIR devices, which are novel disposable aerosol-conducting airway connectors for infants. The company has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Discovery Laboratories Inc.

Corporate Governance 
Discovery Laboratories Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 10. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. John G. Cooper , 55
Chief Exec. Officer, Pres and Director
493.00K0.00
Dr. Thomas F. Miller Ph.D., MBA, 43
Chief Operating Officer and Sr. VP
380.00K0.00
Ms. Mary B. Templeton Esq., 67
Sr. VP, Gen. Counsel and Corp. Sec.
303.00K0.00
Dr. Russell G. Clayton Sr., D.O, 53
Sr. VP of R&D
336.00K0.00
Mr. John A. Tattory , 48
Chief Financial Officer, Chief Accounting Officer and Sr. VP
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders